Alejandro Ayala, MD

Crinetics Pharmaceuticals
San Diego, California, United States

Disclosure information not submitted.

Presentation(s):

• ORF32-01 - Model-Informed Atumelnant Dose Selection for a Phase 3 Study in Adult Patients with Classic Congenital Adrenal Hyperplasia

  Sunday, June 14, 2026
  1:45 PM - 1:50 PM CT

• ORF32-04 - Once Daily Atumelnant (CRN04894) Enables Lowering of Glucocorticoid Doses with Sustained Androgen Reduction in Adults with Congenital Adrenal Hyperplasia

  Sunday, June 14, 2026
  2:10 PM - 2:25 PM CT